I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig
Pipeline Reshuffle:
I-Mab has paused the development of uliledlimab, a CD73 antibody, to focus on givastomig, a CLDN18.2 x 4-1BB bispecific antibody15.
Givastomig Focus:
Givastomig is being prioritized for the first-line treatment of metastatic gastric cancers and has potential in other solid tumors1.
Uliledlimab Pause:
The pause allows data from an ongoing China-only study evaluating uliledlimab in combination with toripalimab in CD73-high NSCLC patients to mature. Development could continue based on trial outcomes1.
Givastomig Trial Results:
Phase I trial data showed a 16.3% overall response rate, including seven partial responses at doses between 5mg/kg and 18mg/kg, with a favorable safety profile1.
Financial Impact:
I-Mab's stock price increased 17.89% upon the announcement, and the company estimates it has enough cash to fund the Phase I givastomig study through dose expansion data readouts and further development initiatives into 202712.
Partnerships:
Givastomig is being jointly developed through a global partnership with ABL Bio, with I-Mab as the lead party in most countries worldwide1.
Sources:
1. https://www.clinicaltrialsarena.com/news/imab-pauses-development-cd73-antibody-pipeline-reshuffle/
2. https://ir.i-mabbiopharma.com/news-releases/news-release-details/i-mab-reports-1h-2024-financial-results-pipeline-progress-and